137 related articles for article (PubMed ID: 10572309)
21. OBTAINING OF THE TRANSGENIC HELIANTHUS TUBEROSUS L. PLANTS, CALLUS AND "HAIRY" ROOT CULTURES ABLE TO EXPRESS THE RECOMBINANT HUMAN INTERFERON ALPHA-2b GENE.
Maistrenko OM; Luchakivska YS; Zholobak NM; Spivak MY; Kuchuk MV
Tsitol Genet; 2015; 49(5):38-44. PubMed ID: 26638495
[TBL] [Abstract][Full Text] [Related]
22. ELISA measurement of interferons.
Garrison TL; Hung F; Izotova L; Schwartz B; Lavoie T; Lee-Own FV
Biotechniques; 2002 Oct; Suppl():98-100. PubMed ID: 12395933
[No Abstract] [Full Text] [Related]
23. [Production of purified human recombinant alpha2b-interferon].
Mel'nik AI; Orlovskaia IV; Zholobak NM; Spivak NIa
Mikrobiol Z; 2012; 74(3):72-8. PubMed ID: 22830200
[TBL] [Abstract][Full Text] [Related]
24. Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.
Boulestin A; Kamar N; Legrand-Abravanel F; Sandres-Saune K; Alric L; Vinel JP; Rostaing L; Izopet J
Antimicrob Agents Chemother; 2004 Sep; 48(9):3610-2. PubMed ID: 15328140
[TBL] [Abstract][Full Text] [Related]
25. [Protein adsorption at the tips from synthetic polymers as the cause of incorrect titer analysis of interferons in antiviral bioassays].
Tonew M; Ohme E; Gerlach D; Wondraczek RH
Z Med Lab Diagn; 1991; 32(2):108-13. PubMed ID: 1648851
[TBL] [Abstract][Full Text] [Related]
26. Virus-specific effects of recombinant porcine interferon-gamma and the induction of Mx proteins in pig cells.
Horisberger MA
J Interferon Res; 1992 Dec; 12(6):439-44. PubMed ID: 1337754
[TBL] [Abstract][Full Text] [Related]
27. Partial inhibition of vesicular stomatitis virus by the interferon-induced human 9-27 protein.
Alber D; Staeheli P
J Interferon Cytokine Res; 1996 May; 16(5):375-80. PubMed ID: 8727077
[TBL] [Abstract][Full Text] [Related]
28. Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.
Kawamoto S; Oritani K; Asada H; Takahashi I; Ishikawa J; Yoshida H; Yamada M; Ishida N; Ujiie H; Masaie H; Tomiyama Y; Matsuzawa Y
J Virol; 2003 Sep; 77(17):9622-31. PubMed ID: 12915574
[TBL] [Abstract][Full Text] [Related]
29. [Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro].
Wang HQ; Ma LL; Jiang JD; Pang R; Chen YJ; Li YH
Yao Xue Xue Bao; 2014 Nov; 49(11):1547-53. PubMed ID: 25757280
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-gamma and HuIFN-alpha or HuIFN-beta.
Oleszak E; Stewart WE
J Interferon Res; 1985; 5(2):361-71. PubMed ID: 2989390
[TBL] [Abstract][Full Text] [Related]
31. Biologic activity in a fragment of recombinant human interferon alpha.
Ackerman SK; Zur Nedden D; Heintzelman M; Hunkapiller M; Zoon K
Proc Natl Acad Sci U S A; 1984 Feb; 81(4):1045-7. PubMed ID: 6199790
[TBL] [Abstract][Full Text] [Related]
32. Antiviral effects of recombinant tumour necrosis factor in vitro.
Mestan J; Digel W; Mittnacht S; Hillen H; Blohm D; Möller A; Jacobsen H; Kirchner H
Nature; 1986 Oct 30-Nov 5; 323(6091):816-9. PubMed ID: 3022155
[TBL] [Abstract][Full Text] [Related]
33. Comparative analysis of interferon and antiviral protein messenger RNAs.
Ershov FI; Sokolova TM; Tazulakhova EB; Kadyrova AA; Kisling U; Novokhatsky AS
Acta Virol; 1979 Jan; 23(1):32-9. PubMed ID: 35956
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the biological activities and physicochemical characteristics of recombinant bovine interferon-α₁₄.
Shao J; Cao C; Bao J; Gao M; Wang J
Mol Immunol; 2015 Mar; 64(1):163-9. PubMed ID: 25480392
[TBL] [Abstract][Full Text] [Related]
35. Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes.
Shiffman ML; Verbeke SB; Kimball PM
Antiviral Res; 2000 Nov; 48(2):91-9. PubMed ID: 11114411
[TBL] [Abstract][Full Text] [Related]
36. Regulation of macrophage growth and antiviral activity by interferon-gamma.
Goldberg M; Belkowski LS; Bloom BR
J Cell Biol; 1989 Sep; 109(3):1331-40. PubMed ID: 2549078
[TBL] [Abstract][Full Text] [Related]
37. [How to make an ally of an "inactive" product: the example of interferon].
Lavelle F
Bull Cancer; 2000 Sep; 87(9):621-2. PubMed ID: 11184449
[No Abstract] [Full Text] [Related]
38. Potency stability of recombinant (Serine-17) human interferon-beta.
Geigert J; Ziegler DL; Panschar BM; Creasey AA; Vitt CR
J Interferon Res; 1987 Apr; 7(2):203-11. PubMed ID: 3039014
[TBL] [Abstract][Full Text] [Related]
39. Study of the antiviral activity of some new classes of AS-triazine derivatives (preliminary note).
Tomas E; Popescu A; Zuivertz A; Jucu V; Czabor F; Cristescu C
Rom J Virol; 1995; 46(1-2):51-6. PubMed ID: 9106401
[TBL] [Abstract][Full Text] [Related]
40. A recombinant human interferon-alpha B/D hybrid with a broad host-range.
Horisberger MA; de Staritzky K
J Gen Virol; 1987 Mar; 68 ( Pt 3)():945-8. PubMed ID: 3029315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
